Switzerland
At Alexion, our mission is to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, as well as supportive technologies and healthcare services.
For over three decades, patients and their caregivers have been at the centre of everything we do. Everyday, we are inspired to think differently and follow the science in order to create better outcomes for them and their families. Our mission is driven by understanding who they are as unique individuals, not just their disease.
In Switzerland, we work across various rare diseases and devastating conditions, including:
- Paroxysmal Nocturnal Haemoglobinuria (PNH) – a rare, chronic, progressive and potentially life-threatening blood disorder. It is characterised by red blood cell destruction within blood vessels (also known as intravascular haemolysis) and white blood cell and platelet activation, which can result in thrombosis (blood clots).
- Atypical Haemolytic Uraemic Syndrome (aHUS) – a rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots.
- Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN) – a rare, progressive, genetic condition characterized by non-malignant (non-cancerous) tumors called plexiform neurofibromas (PN) that develop in the brain, and along the spinal cord and nerve.
- Generalised Myasthenia Gravis (gMG) – a rare, autoimmune neuromuscular disease characterised by loss of muscle function and severe muscle weakness.
- Neuromyelitis Optica Spectrum Disorder (NMOSD) – a rare autoimmune disease of the central nervous system, characterised by unpredictable relapses which can result in cumulative disability.
- Hypophosphatasia (HPP) – a rare, genetic (inherited), metabolic disease characterized by impaired mineralization (“calcification”), the process that hardens and strengthens bones and teeth. This can lead to poor growth and development, weakness and deformity of bones and other skeletal abnormalities, and premature loss of teeth with the root intact.
- Lysosomal Acid Lipase Deficiency (LAL-D) – a genetic, and progressive ultra-rare metabolic disease associated with multiorgan damage in infant, paediatric and adult patients, and premature death in infants.
Clinical Trials
Alexion is committed to serving people affected by rare diseases through the discovery, development and access of life-changing medicines. Our goal is to bring safe and effective medicines to as many patients as possible by conducting rigorous clinical trials and obtaining marketing approval by regulatory authorities around the world. Our work is marked by a commitment to the highest standards of preclinical and clinical research, and an acute sense of urgency. As such, we prioritize access to our investigational medicines through participation in a clinical trial.
To inquire about a clinical trial, please contact clinicaltrials@alexion.com.
Transparency and Disclosure
Careers
At Alexion, we foster an environment that attracts and retains the best talent. We provide the tools to enable each individual to perform at their personal best so that we maximize our collective impact.
Explore career opportunities at Alexion here: